AVIR vs. INO, DAWN, MIRM, ABCL, ELVN, COLL, PRTA, ARQT, SAVA, and GYRE
Should you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Inovio Pharmaceuticals (INO), Day One Biopharmaceuticals (DAWN), Mirum Pharmaceuticals (MIRM), AbCellera Biologics (ABCL), Enliven Therapeutics (ELVN), Collegium Pharmaceutical (COLL), Prothena (PRTA), Arcutis Biotherapeutics (ARQT), Cassava Sciences (SAVA), and Gyre Therapeutics (GYRE). These companies are all part of the "medical" sector.
Inovio Pharmaceuticals (NASDAQ:INO) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.
Inovio Pharmaceuticals has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500.
Inovio Pharmaceuticals received 700 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 71.49% of users gave Inovio Pharmaceuticals an outperform vote while only 47.22% of users gave Atea Pharmaceuticals an outperform vote.
Inovio Pharmaceuticals presently has a consensus price target of $70.67, indicating a potential upside of 580.14%. Given Atea Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Inovio Pharmaceuticals is more favorable than Atea Pharmaceuticals.
Inovio Pharmaceuticals has higher earnings, but lower revenue than Atea Pharmaceuticals.
Atea Pharmaceuticals has a net margin of 0.00% compared to Atea Pharmaceuticals' net margin of -16,238.91%. Inovio Pharmaceuticals' return on equity of -29.18% beat Atea Pharmaceuticals' return on equity.
In the previous week, Inovio Pharmaceuticals had 3 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 6 mentions for Inovio Pharmaceuticals and 3 mentions for Atea Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 1.25 beat Atea Pharmaceuticals' score of 0.62 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.
26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 2.5% of Inovio Pharmaceuticals shares are owned by insiders. Comparatively, 17.8% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Inovio Pharmaceuticals beats Atea Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Atea Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atea Pharmaceuticals Competitors List
Related Companies and Tools
